Mary T. Szela
Mary T. Szela's purchase track record
How the stock did after each of Mary T. Szela's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2026 | ABSI | $149K | -12.5% | pending | — |
| 5/15/2026 | TLSI | $103K | +96.6% | pending | — |
| 2/23/2026 | TLSI | $125K | -35.5% | +2.4% | +11.9% |
| 1/27/2025 | TLSI | $102K | +7.9% | -14.1% | +6.3% |
| 9/10/2024 | TLSI | $100K | -22.9% | +2.0% | +1.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
ABSI to Report Q3 2026 Results on Nov 12, Shares Drop. Absci will announce its third‑quarter 2026 financials on Nov. 12. The company’s shares fell after a recent analyst note that the stock trades near the lower end of its 52‑week range and a new price target of $14.50. The drop follows a whale‑level buying alert and a broader market move higher for several large names. The upcoming earnings release may clarify the company’s outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TriSalus Stock Rises After FDA Clears TriNav Advance. TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.
Transaction History
| TLSIW | ▼ Sell | Tax Withholding | 2,693 | $12K | 10/5/2026 | View on chart |
| ABSI | ▲ Buy | Open Market | 12,900 | $149K | 6/30/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 3,990 | $15K | 6/30/2026 | View on chart |
| ABSI | ▲ Buy | Grant | 10,100 | $0 | 6/4/2026 | View on chart |
| TLSI | ▲ Buy | Open Market | 39,682 | $103K | 5/15/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 15,944 | $61K | 3/17/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 4,358 | $18K | 3/11/2026 | View on chart |
| TLSI | ▲ Buy | Open Market | 30,487 | $125K | 2/23/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 125,000 | $0 | 11/24/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 300,000 | $0 | 11/24/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 21,089 | $0 | 2/18/2025 | View on chart |
| TLSI | ▲ Buy | Open Market | 5,010 | $26K | 1/30/2025 | View on chart |
| TLSI | ▲ Buy | Open Market | 5,030 | $25K | 1/29/2025 | View on chart |
| TLSI | ▲ Buy | Open Market | 4,716 | $24K | 1/28/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 40,000 | $0 | 1/27/2025 | View on chart |
| TLSI | ▲ Buy | Open Market | 4,826 | $26K | 1/27/2025 | View on chart |
| TLSI | ▲ Buy | Open Market | 1,295 | $6K | 9/13/2024 | View on chart |
| TLSI | ▲ Buy | Open Market | 6,000 | $30K | 9/13/2024 | View on chart |
| TLSI | ▲ Buy | Open Market | 7,520 | $39K | 9/12/2024 | View on chart |
| TLSI | ▲ Buy | Open Market | 5,000 | $25K | 9/10/2024 | View on chart |
| TLSI | ▲ Buy | Grant | 84,899 | $0 | 2/13/2024 | View on chart |
| TLSI | ▲ Buy | Grant | 125,000 | $0 | 2/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TriSalus Warrant Gains After FDA Clears TriNav Advance
TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.
TriSalus Warrant Gains After FDA Clears TriNav Advance. TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.